Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -58.67 | -48.86 | -30.79 | |
| Graham Fair Price | -70.52 | 16.34 | 55.44 | |
| PEG | -93.29 | 0.02 | 0.27 | |
| Price/Book | 2105.34 | 44.00 | -2.00 | |
| Price/Cash Flow | -32.89 | -54.71 | -41.17 | |
| Prices/Earnings | -34.38 | 4.98 | -7.58 | |
| Price/Sales | -99.02 | 168.87 | 17227.27 | |
| Price/FCF | -32.89 | -54.71 | -41.17 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -3.72 | 0.96 | 1.00 | |
| Operating Margin | -98.50 | 8.48 | -566.44 | |
| ROA | 57.26 | 0.38 | -0.24 | |
| ROE | 0.07 | 2.21 | 3260.81 | |
| ROIC | 0.07 | 0.53 | 633.25 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.41 | -0.01 | 3080.54 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.55 | 2.75 | 403.63 | |
| EPS QOQ | -0.28 | 2.71 | 878.56 | |
| FCF QOQ | -0.61 | 0.14 | -76.98 | |
| Revenue QOQ | -0.79 | 115.65 | 14601.05 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 312.98 | 100.00 | |
| Days Sales Outstanding (DSO) | -2636.77 | 89.67 | -96.60 | |
| Inventory Turnover | 0.00 | 0.29 | 100.00 | |
| Debt/Capitalization | -0.08 | 0.66 | 745.34 | |
| Quick Ratio | 5.77 | 2.82 | -51.14 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | -45.57 | 2.32 | -94.91 | |
| Cash | 8.69 | 8.77 | 0.91 | |
| Capex | < 0.005 | < 0.005 | -90.59 | |
| Free Cash Flow | -2.21 | -1.86 | 15.61 | |
| Revenue | < 0.005 | 0.60 | 11340.56 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Best
Fundamentals
Financial Health
06 - Financial Health ·
Bad